- The database offers a wide collection of well-established tumor models
- Updates shall provide an increased depth of data for gene expression and WES
Charles River Laboratories International, Inc., an early-stage contract research organization (CRO), recently announced updates for its online Tumor Model Compendium. The cancer model database of Charles River offers access to a wide collection of tumor models that are well-established for early-stage oncology research.
Apparently, the update adds up about 79 new patient-derived xenografts (PDX), 36 new cell line (CL) models and 10 cell line-derived xenografts (CDX) for numerous cancer types that include colon, lung, renal and anal cancer as well as melanoma and leukemia. Furthermore, these updates will provide an increased depth of data for gene expression and whole exome sequencing (WES) with a larger coverage of bioinformatics.
The compendium offered by Charles River involves tumor models from an extensive range of various tumor subtypes for in vitro and in vivo oncology research including cell line-derived xenografts (CDX), syngeneic models and patient-derived xenografts (PDXs). When this compendium is combined with the sturdy portfolio of oncology service and scientific background of the company, it offers a highly translational platform for safe and effective oncology therapeutics development.
Reportedly, Charles River had unveiled in vivo tumor microdialysis recently in order to support its cancer research. Microdialysis is essentially a powerful and uniquely sensitive method to sample tumor microenvironment of research models. With the help of microdialysis, researchers collect other actionable data as they perform better and efficient decision making.
On the traditional application to neuroscience research, microdialysis within tumor models shall offer an outstanding approach to model the pharmacokinetics of a given compound.
According to reliable sources, Charles River launched an extended form of its PDX portfolio in the North America region. The company has experience of more than 30 years and the benefits from it have armed global PDX of Charles River with capabilities to provide all the clients with necessary scientific guidance to help them progress cancer therapeutics.
Source Credit- https://www.biospace.com/article/releases/charles-river-laboratories-updates-tumor-model-compendium/